A Comparative Study of Extracellular Vesicle-associated and Cell-free DNA and RNA for HPV Detection in Oropharyngeal Squamous Cell Carcinoma
Authors
Affiliations
Purpose: This study compares the detection sensitivity of two separate liquid biopsy sources, cell-free (cf) DNA/RNA and extracellular vesicle (EV)-associated DNA/RNA (EV-DNA/RNA), to identify circulating Human Papilloma Virus (HPV) DNA/RNA in plasma obtained from patients with oropharyngeal squamous cell carcinoma (OPCSCC). We also report on the longitudinal changes observed in HPV-DNA levels in response to treatment.
Experimental Design: A prospective study was conducted that included 22 patients with locally advanced disease and six patients with metastatic OPCSCC. Twenty-three patients had HPV-related OPCSCC defined by p16 immunohistochemistry. Levels of circulating HPV-DNA and HPV-RNA from plasma-derived cf-DNA/RNA and EV-DNA/RNA were quantified using digital droplet PCR.
Results: Circulating HPV-DNA was detected with higher sensitivity in cf-DNA compared to EV-DNA at 91% vs. 42% (p = <0.001). Similarly, circulating tumoral HPV-RNA was detected at a higher sensitivity in cf-RNA compared to EV-RNA, at 83% vs. 50% (p = 0.0019). In the locally advanced cohort, 100% (n = 16) of HPV-OPCSCC patients demonstrated a reduction in circulating HPV-DNA levels in cf-DNA following curative treatment, with 81% of patients demonstrating complete clearance to undetectable levels. However, in metastatic HPV-OPCSCC patients (n = 4), HPV-DNA levels did not correlate with treatment response.
Conclusion: Our study demonstrates that although HPV-DNA/RNA can be detected in EV associated DNA/RNA, cf-DNA/RNA is the more sensitive liquid biopsy medium. As circulating HPV-DNA levels were found to only correlate with treatment response in the locally advanced but not metastatic setting in our small cohort of patients, the use of HPV-DNA as a dynamic biomarker to monitor treatment response requires further evaluation.
Migliorelli A, Ciorba A, Manuelli M, Stomeo F, Pelucchi S, Bianchini C Diagnostics (Basel). 2024; 14(23).
PMID: 39682570 PMC: 11640492. DOI: 10.3390/diagnostics14232662.
Guo S, Wang X, Shan D, Xiao Y, Ju L, Zhang Y Biomark Res. 2024; 12(1):123.
PMID: 39402599 PMC: 11476736. DOI: 10.1186/s40364-024-00661-2.
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.
Krsek A, Baticic L, Braut T, Sotosek V Biomolecules. 2024; 14(8).
PMID: 39199313 PMC: 11352962. DOI: 10.3390/biom14080925.
Rosing F, Meier M, Schroeder L, Laban S, Hoffmann T, Kaufmann A Microbiol Spectr. 2024; 12(7):e0002424.
PMID: 38829114 PMC: 11218464. DOI: 10.1128/spectrum.00024-24.
Li G, Wang H, Zhong J, Bai Y, Chen W, Jiang K Br J Cancer. 2024; 130(6):925-933.
PMID: 38238428 PMC: 10951262. DOI: 10.1038/s41416-024-02575-0.